Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Kraig Biocraft Laboratories (KBLB) Net Cash Flow (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed Net Cash Flow for 11 consecutive years, with -$456594.0 as the latest value for Q4 2022.

  • Quarterly Net Cash Flow fell 34.84% to -$456594.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2022, down 1.66% year-over-year, with the annual reading at $1.1 million for FY2025, 159.46% up from the prior year.
  • Net Cash Flow hit -$456594.0 in Q4 2022 for Kraig Biocraft Laboratories, up from -$500456.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $2.7 million in Q2 2021 to a low of -$973871.0 in Q3 2021.
  • Historically, Net Cash Flow has averaged $303102.4 across 4 years, with a median of -$8642.0 in 2018.
  • Biggest five-year swings in Net Cash Flow: soared 2843.25% in 2019 and later plummeted 67.37% in 2022.
  • Year by year, Net Cash Flow stood at -$8642.0 in 2018, then skyrocketed by 10444.3% to $893954.0 in 2019, then crashed by 137.88% to -$338609.0 in 2021, then tumbled by 34.84% to -$456594.0 in 2022.
  • Business Quant data shows Net Cash Flow for KBLB at -$456594.0 in Q4 2022, -$500456.0 in Q3 2022, and $894182.0 in Q2 2022.